U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures ...

Rapport Therapeutics announced in early January 2026 that the FDA has cleared RAP-219 to move into Phase 3 registrational trials for focal onset seizures, while the company advances a broader ...

BOSTON and SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and ...

In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted ...

Rapport Therapeutics recently presented new data and post hoc analyses from its Phase 2a trial of RAP-219 in drug-resistant focal onset seizures at the 2025 American Epilepsy Society Meeting, showing ...

Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well tolerated Patients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% ...

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarte ...

(MENAFN- GlobeNewsWire - Nasdaq) New analysis examines RAP-219's effect during the first month of treatment and consistency of efficacy over the treatment period, effectiveness across baseline disease ...

BOSTON and SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Rapport Therapeutics, Inc. (Nasdaq: RAPP), please note the references to the ...